SELLAS LIFE SCIENCES GROUP I (SLS) Stock Price & Overview
NASDAQ:SLS • US81642T2096
Current stock price
The current stock price of SLS is 4.86 USD. Today SLS is up by 2.1%. In the past month the price decreased by -9.33%. In the past year, price increased by 270.99%.
SLS Key Statistics
- Market Cap
- 872.759M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.25
- Dividend Yield
- N/A
SLS Stock Performance
SLS Stock Chart
SLS Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to SLS. When comparing the yearly performance of all stocks, SLS is one of the better performing stocks in the market, outperforming 97.56% of all stocks.
SLS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SLS. No worries on liquidiy or solvency for SLS as it has an excellent financial health rating, but there are worries on the profitability.
SLS Earnings
SLS Forecast & Estimates
7 analysts have analysed SLS and the average price target is 8.84 USD. This implies a price increase of 81.89% is expected in the next year compared to the current price of 4.86.
SLS Groups
Sector & Classification
SLS Financial Highlights
Over the last trailing twelve months SLS reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 51.92% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.29% | ||
| ROE | -37.9% | ||
| Debt/Equity | 0 |
SLS Ownership
SLS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.18 | 365.196B | ||
| AMGN | AMGEN INC | 15.37 | 188.577B | ||
| GILD | GILEAD SCIENCES INC | 15.89 | 172.567B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.81 | 111.931B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.12 | 78.916B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.72 | 44.163B | ||
| INSM | INSMED INC | N/A | 32.624B | ||
| NTRA | NATERA INC | N/A | 28.615B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 27.011B | ||
| BIIB | BIOGEN INC | 11.1 | 25.883B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.79 | 25.318B | ||
| MRNA | MODERNA INC | N/A | 20.099B | ||
| INCY | INCYTE CORP | 12.62 | 19.015B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SLS
Company Profile
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The company went IPO on 2008-03-12. The firm is focused on the development of therapeutics for a range of cancer indications. The firm's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The firm is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Company Info
IPO: 2008-03-12
SELLAS LIFE SCIENCES GROUP I
7 Times Square, Suite 2503
New York City NEW YORK 10018 US
CEO: Angelos M. Stergiou
Employees: 15
Phone: 16462005278
SELLAS LIFE SCIENCES GROUP I / SLS FAQ
What does SLS do?
SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. The company is headquartered in New York City, New York and currently employs 15 full-time employees. The company went IPO on 2008-03-12. The firm is focused on the development of therapeutics for a range of cancer indications. The firm's product candidates are galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9) inhibitor. GPS is a cancer immunotherapeutic agent licensed by Memorial Sloan Kettering Cancer Center (MSK), that targets the WT1 protein, which is present in an array of tumor types. GPS has potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic malignancies and solid tumor indications. The firm is developing SLS009, which is licensed by GenFleet Therapeutics (Shanghai), Inc., for all therapeutic and diagnostic uses in the world outside of mainland China, Hong Kong, Macau, and Taiwan.
Can you provide the latest stock price for SELLAS LIFE SCIENCES GROUP I?
The current stock price of SLS is 4.86 USD. The price increased by 2.1% in the last trading session.
What is the dividend status of SELLAS LIFE SCIENCES GROUP I?
SLS does not pay a dividend.
What is the ChartMill rating of SELLAS LIFE SCIENCES GROUP I stock?
SLS has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting SLS stock to perform?
7 analysts have analysed SLS and the average price target is 8.84 USD. This implies a price increase of 81.89% is expected in the next year compared to the current price of 4.86.
What is the GICS sector and industry of SLS stock?
SELLAS LIFE SCIENCES GROUP I (SLS) operates in the Health Care sector and the Biotechnology industry.
When does SELLAS LIFE SCIENCES GROUP I (SLS) report earnings?
SELLAS LIFE SCIENCES GROUP I (SLS) will report earnings on 2026-05-11.